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a  b  s  t  r  a  c  t
The  role of the redox state  of Kv  subunits  in the  modulation  of  Kv1  potassium  channels  has  been  well
documented  over  the  past  few  years.  It  has  been  suggested  that  a molecule  that  binds  to or  inhibits  the
aldo-keto  reductase  activity  of  Kv  might  affect  the  modulation  of  channel  properties.  Previous  studies
of  possible  modulators  of  channel  activity  have  shown  that  cortisone  and  some  related  compounds  are
able to physically  dissociate  the  channel  components  by binding  to a site at the  interface  between   and
  subunits.  Herein,  we  describe  some  new  inhibitors  of rat brain  Kv2,  identified  using  an  assay  based
on  multiple  substrate  turnover.  This  approach  allows  one  to focus  on molecules  that  specifically  block
NADPH  oxidation.  These  studies  showed  that,  at 0.5  mM,  3,4-dihydroxphenylacetic  acid (DOPAC)  was
an inhibitor  of Kv2 turnover  yielding  a ∼40–50% reduction  in the aldehyde  reductase  activity  of  this
subunit.  Other  significant  inhibitors  include  the  bioflavinoid,  rutin  and  the  polyphenol  resveratrol;  some
of the known  cardioprotective  effects of  these  molecules  may  be  attributable  to  Kv1  channel  modulation.
Cortisone  or  catechol  caused  moderate  inhibition  of  Kv2  turnover,  and  the aldo-keto  reductases  inhibitor
valproate  had  an  even  smaller  effect.
Despite the importance  of  the  Kv1  channels  in a  number  of  disease  states,  there  have  been  few Kv2
inhibitors  reported.  While  the  ones  identified  in this  study  are  only  effective  at high  concentrations,  they
could serve  as tools  to decipher  the  role of Kv2  in vivo  and,  eventually,  inform  the  development  of novel
therapeutics.
© 2014  Published  by  Elsevier  Ltd.
1. Introduction
The Shaker voltage-gated K+ channels (Kv1 superfamily) con-
trol the efflux of K+ through cell membranes and, thereby, dampen
membrane excitability. An auxillary -subunit (Kv), associated
with the cytoplasmic face of Kv proteins (Dolly et al., 1994; Parcej
et al., 1992; Scott et al., 1994) has sequence homology with aldo-
keto reductase (AKR) enzymes (Gulbis et al., 1999; Long et al., 2005).
The catalytic C-terminal of Kv2  has a tightly, but non-covalently,
bound nicotinamide (NADPH) cofactor. Most significantly, Kv is
known to modulate the channel’s activity in a manner that depends
on the redox state of the bound cofactor. This mechanism is thought
to proceed via redox dependent conformational changes (Weng et
al., 2006; Pan et al., 2008b, 2011). The Kv subunit is catalytically
active as an aldo-keto reductases being able to reversibly oxidise
a range of alcohols to their corresponding aldehydes (Alka et al.,
2010; Tipparaju et al., 2008).
∗ Corresponding author. Tel.: +353 1 402 4408; fax: +353 1 402 4495.
E-mail address: gary.henehan@dit.ie (G.T.M. Henehan).
Allelic deletion of Kv is directly linked to severe epilepsy
including infantile spasm (Heilstedt et al., 2001) while loss-of-
function mutations in pore forming -subunits are associated with
convulsive disorders (Adelman et al., 1995; Guan et al., 2006;
Imbrici et al., 2006, 2007). It has been suggested that inhibitors
of the action of Kv might prove useful as therapeutics (Pan et al.,
2008a, 2012). Despite this, there have been few reports of com-
pounds that might inhibit Kv.
In 2008, Pan et al., screened a number of potential Kv inhibitors
and showed that cortisone can bind to Kv proteins at two differ-
ent sites: one close to the enzyme bound NADPH and another at
the interface between Kv and Kv1  subunits (Pan et al., 2008a).
They further showed that cortisone promotes dissociation of Kv
from Kv1 subunits, a finding that focused attention on inhibitors
that might target the interface between subunits in Kv1 chan-
nels. Subsequently, these authors tested 25 cortisone analogues
for their ability to potentiate Kv1 channels by binding to Kv and
promoting its dissociation (Pan et al., 2012). Their work identi-
fied fluticasone as a potential lead for designing more efficient
small molecules that might influence channel function by disso-
ciating the Kv1–Kv assembly. Nevertheless, there is little or no
http://dx.doi.org/10.1016/j.biocel.2014.07.013
1357-2725/© 2014 Published by Elsevier Ltd.
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information on molecules, other than substrates and corticoste-
roids, that can bind to the active site of the Kv subunit. Predicting
inhibitors for this protein is difficult since even studies on substrate
specificity have proven somewhat confusing (Alka et al., 2010;
Tipparaju et al., 2008).
Herein, the interactions of a variety of small molecules with
the active site of Kv2 were probed. The tightly bound NADPH on
Kv2  may  dissociate and allow measurement of multiple turnovers
(Weng et al., 2006). We  exploit this activity to screen for Kv2
inhibitors that have a direct influence on substrate turnover. This
approach utilised a simple HPLC-based assay to monitor the Kv2-
catalysed reduction of 4-nitrobenzaldehyde (see Alka et al., 2010).
This assay was used for screening of small molecule inhibitors that
might bind to Kv2  and inhibit the redox reaction. In this way,
inhibitors were sought for NADPH oxidation rather than modu-
lators of channel function, since this oxidation step is known to
influence channel activity.
2. Materials and methods
2.1. Overexpression and purification of Kvˇ2
The rat brain Kv2 protein was overexpressed in, and puri-
fied from, Escherichia coli BL21 (DE3, plysS) cells transformed
with the pET15b-Kv2 construct containing an N-terminal His-tag,
described in Alka et al., 2010. The purified protein was dialysed
against 2 L of prechilled 0.2 M potassium phosphate, pH 7.5 for 36 h
with three changes.
2.2. HPLC assay for measuring the inhibition of Kvˇ2-mediated
4-nitrobenzaldehyde reduction
Two different HPLC separation methods (Isocratic and Gradient)
were used to carry out the inhibition studies for the Kv2 mediated-
reduction of 4-nitrobenzaldehyde. The one chosen depended on
the effective separation of the inhibitor from components of
the reaction mixture. All inhibition studies were carried out in
duplicate in 0.2 M potassium phosphate buffer, pH 7.5 contain-
ing 0.2 mM NADPH at 37 ◦C in the presence of ∼0.5 mg  of Kv2,
an appropriate concentration of each test inhibitor and 500 M
of 4-nitrobenzaldehyde as substrate (final volume of 0.25 ml). A
100 mM stock solution of all inhibitors was prepared in DMSO.
The concentration of DMSO in the assay mixture was  less than
or equal to 1% (v/v). DMSO at this concentration was found to
have no effect on the 4-nitrobenzaldehyde reductase activity of
Kv2. The inhibitor was incubated with the enzyme for 20 min
before the addition of substrate, which was added last, and the
reaction further incubated for 30 min  at 22 ◦C before quenching by
adding an equal volume of the HPLC mobile phase consisting of
methanol/trifluroacetic acid/water (60: 0.1: 39.9, v/v/v). Aliquots,
(10 l), of the resultant mixture were analysed on a Nucleosil C18
(3.9 × 150 mm)  HPLC column, using Waters 2695 family of Separa-
tions modules (Waters Corporation, Milford, USA) with monitoring
by a Waters 2998 photodiode array detector at 274 nm. The col-
umn  temperature was 37 ◦C. Controls without enzyme were used
to monitor any background reaction between the inhibitor and the
substrate 4-nitrobenzaldehyde.
2.2.1. Gradient HPLC assay
Solvent A was a mixture of methanol/trifluroacetic acid/water
(60: 0.1: 39.9) while solvent B comprised methanol/trifluroacetic
acid/water (20: 0.1: 79.9). The following linear gradient was
used for the separation: 20–100% B (15 min), 100% B (5 min) and
100–20% B (0.1 min) at 0.9 mL/min. The run time was 20 min.
Standard curves constructed using each method separately for
4-nitrobenzaldehyde and 4-nitrobenzyl alcohol were used to deter-
mine concentrations of product in each of the reaction mixtures.
2.2.2. Isocratic elution method
Solvent A (100%) was  used as mobile phase with a total acqui-
sition time of 10 min  for the isocratic elusion method while the
procedure for determination of product concentration was  the
same as described above (Section 2.2.1)
2.3. Fluorescence measurement of inhibitor binding to Kvˇ2
Fluorescence scans of Kv2  with bound NADPH were recorded
on a Perkin Elmer fluorescence spectrometer LS50B at 22 ◦C. Bind-
ing studies were carried out in a quartz cuvette containing ∼2.0 M
Kv2-bound NADPH in 0.2 M potassium phosphate buffer, pH 7.5 at
22 ◦C. The reaction volume was  2 ml.  All inhibitor solutions (Stock
concentration 100 mM)  were prepared in DMSO and then diluted
into 0.2 M potassium phosphate buffer, pH 7.5 to the required con-
centration, keeping the content of DMSO in the reaction mixture
equal to or below 1% (v/v). DMSO at this concentration had no effect
on enzyme-bound NADPH. The fluorimeter excitation wavelength
used was 360 nm with a slit size of 15 nm and emission spectra were
acquired from 300 to 600 nm.  After a spectrum was  recorded, 10 l
of inhibitor stock solution was  added into the Kv2 solution and
mixed. A spectrum was recorded immediately after mixing (1 min)
and at different time points afterwards.
3. Results and discussion
3.1. Inhibitors of the ˇ-subunit from voltage-sensitive potassium
channels
Table 1 shows the compounds tested for their ability to inhibit
Kv2-mediated reduction of 4-nitrobenzaldehyde. Although it has
previously proven somewhat difficult to find molecules that bind
to Kv2  as inhibitors in this study several molecules were found
that were capable of binding to, and inhibiting, Kv2.
3.1.1. DOPAC and catechol
3,4-Dihydroxphenylacetic acid (DOPAC), the acid metabolite
of dopamine inhibited Kv2  in a concentration-dependent and
saturable manner (Fig. 1A). Under the conditions used in this
study, DOPAC was found to be the most effective inhibitor of
Kv2 of all the molecules tested, showing ∼40% reduction in 4-
nitrobenzaldehyde reductase activity (Table 1). The inhibition was
found to be concentration dependent (Fig. 1A). Interestingly, cat-
echol, which has a structure like DOPAC but without the acetate
group, was found to be far less effective (16% Inhibition, see Table 1).
While the observed DOPAC inhibition is only 40%, it is of interest
to find that this neurotransmitter metabolite is capable of binding
to Kv2, particularly considering findings regarding the role of Kv1
channels in regulating dopamine release (see Martel et al., 2011).
3.1.2. Cortisone
Structural studies have shown cortisone to bind at two differ-
ent sites on Kv2: one close to the NADPH cofactor binding site and
another at an interface site between the  and  subunits (Pan et
al., 2008a). It was, therefore, expected that cortisone might inhibit
Kv2. Indeed, this study shows that cortisone does inhibit Kv2
activity but only by ∼18% (Table 1). This inhibition was further
shown to be concentration dependent (Fig. 1B). Such a relatively
modest inhibition by cortisone supports the idea that its main effect
on channel activity is likely via dissociation of Kv2 from Kv1 (Pan
et al., 2008a).
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Table  1
Inhibitors of Kv2-mediated aldehyde reduction. All data are expressed as mean of triplicate measurements.
Inhibitor (0.5 mM) Description of inhibitor Percentage inhibitiona
Sodium valproate Classical AKR inhibitor/anticonvulsant 10 ± 0.8
4-Nitrobenzoic acid Kv2 catalysed reaction product 0
4-Chlorobenzaldehyde Substrate analogue 6 ± 0.5
4-Fluorobenzaldehyde Substrate analogue 3 ± 0.8
Anisaldehyde Substrate analogue 0
Tolualdehyde Substrate analogue 0
Chloral hydrate Sedative and hypnotic drug 0
4-nitoacetophenone Aromatic ketone 6 ± 0.6
Rutin  hydrate Plant flavanoid 38 ± 2
Resveratrol Chemopreventive/cardioprotective/antiaging 38 ± 1
Cortisone Steroid hormone 18 ± 2
Pyrazole Analgesic/anti-inflammatory 0
Cyproheptadine Antidepressant 0
Amitriptyline hydrochloride Antidepressant 0
d-Sorbitol Sugar alcohol 0
Chlorpromazine hydrochloride Antipsychotic drug 0
DOPAC Dopamine metabolite 40 ± 4
Catechol Structural variant of DOPAC 16 ± 0.7
5-Hydroxyindole-3-acetic acid Serotonin metabolite 0
a The amount of 4-nitrobenzyl alcohol produced as a result of Kv2-mediated multiple turnover of 4-nitrobenzaldehyde with no inhibitor was taken as 100%. Activ-
ities  in the presence of inhibitor were expressed as a percentage of control 4-nitrobenzaldehyde reductase activity. Enzyme activity was measured as described in
Section  2.
3.1.3. Sodium valproate
This anti-convulsant drug, which is a classical inhibitor of many
aldo-keto reductases, (Hinshelwood et al., 2002; Todaka et al.,
2000) proved to be a rather poor inhibitor showing a 20% reduction
in 4-nitrobenzaldehyde activity of Kv2  at 0.5 mM (Table 1).
3.1.4. Rutin
Rutin, a naturally-occurring plant flavanoid known to inhibit
aldose reductase from rat brain (Wermuth et al., 1982), reduced
Kv2 aldehyde reductase activity by ∼38% at 0.5 mM (Table 1).
A concentration-dependent increase in inhibition was  observed
Fig. 1. Concentration dependent inhibition of Kv2 by various inhibitors. The data show the percentage inhibition as a function of increasing concentration of (A) DOPAC
(0–700  M),  (B) cortisone (0–1000 M), (C) rutin (0–2000 M),  (D) Resveratrol (0–2000 m). The assay mixture contained ∼0.5 mg Kv2 in 0.2 M potassium phosphate
buffer  (pH 7.5), along with 500 M 4-nitrobenzaldehyde as substrate, 200 M NADPH and various concentrations of inhibitor in a final reaction volume of 250 l at 37 ◦C.
After  the addition of inhibitor to Kv2 containing NADPH, the reaction was initiated by the addition of the substrate (4-nitrobenzaldehyde) and incubated for 30 min. The
amounts of the reduced product (4-nitrobenzylalcohol) formed were analysed by HPLC, as described in Section 2. Percentage inhibition of the 4-nitrobenzaldehyde reductase
activity of Kv2 at different starting concentrations of inhibitor was  plotted against inhibitor concentration. Data are expressed as the mean of triplicate measurements. The
points  were fitted to a rectangular hyperbolic curve using prism 6.0.
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(Fig. 1C), giving a maximal level of inhibition only slightly less than
that observed with DOPAC.
3.1.5. Resveratrol
Kv2  inhibition by resveratrol was examined since it has been
shown to have chemopreventive, cardioprotective, and anti-ageing
properties which may  be mediated by inhibition of a reductase
(Buryanovskyy et al., 2004). Resveratrol (0.5 mM)  inhibited Kv2
activity in a concentration-dependent manner but to a maximal
level of ∼40% (Fig. 1D). It is interesting to speculate that some
of the cardioprotective effects attributed to resveratrol might be
mediated by Kv2  inhibition.
3.1.6. Other compounds tested
4-Nitrobezoic acid showed no inhibition showing that Kv2
was not liable to product inhibition under these conditions.
anisaldehyde, cyproheptadine, chloral hydrate, d-sorbitol, chlor-
promazine and 5-hydroxyindole-3-acetic acid all failed to inhibit
Kv2. The antidepressants amitriptyline and cyproheptadine (a
known potassium channel blocker, Wooltorton and Mathie, 1993)
were, likewise, devoid of effect on Kv2. The antipsychotic drug,
chlorpromazine and the serotonin metabolite 5-hydroxyindole-3-
acetic acid showed no measurable inhibition of Kv2.
3.1.7. Summary of inhibition findings
As with the substrate specificity studies mentioned above
it is difficult to deduce common features that will define a
Kv2 inhibitor. A variety of aldehydes might be expected to
be inhibitors or substrates. However, the fully hydrated alde-
hyde, chloral hydrate, did not inhibit neither did a several
aromatic aldehydes although 6% inhibition was observed with 4-
chlorobenzaldehyde. Sodium valproate did show some inhibition
(10%) indicating that a carboxylate might be necessary for inhi-
bition, however, 4-nitrobenzoate did not inhibit. On the other
hand, 5-nitroacetophenone did inhibit albeit by only 6%. Catechol
inhibited Kv2 by 16% but DOPAC which consists of catechol bear-
ing an acetate group inhibited by 40%. This again suggests that a
carboxylate is desirable for inhibition. Large multi ring structures
such as amitriptyline, chlorpromazine and cyproheptadine were
not inhibitory presumably due to their bulk. On the other hand the
multi ring structure of rutin was inhibitory. These findings proba-
bly reflect an active site with a high degree of specificity. The most
significant inhibition was observed with DOPAC, rutin hydrate and
resveratrol.
3.2. Inhibitor binding studies
It was possible that some of the compounds tested might be
binding to sites other than the active site of Kv2. In 2008, Pan et
al., identified an interface site that promotes dissociation of Kv2
from Kv1. It is not known if this site will bind cortisone in the
absence of Kv1  subunits. Moreover, because some of the com-
pounds tested might be substrates for Kv2, the binding of the
inhibitors to the Kv2-active site was examined by monitoring the
quenching of the cofactor florescence peak at 450 nm.  This effect on
fluorescence intensity is different from that induced by a substrate,
which oxidises the Kv2-bound NADPH and, thereby, eliminates
the fluorescence peak (Alka et al., 2010; Pan et al., 2008a). Binding
studies carried out for cortisone, DOPAC, catechol, rutin and resver-
atrol yielded reductions in the fluorescence intensity at 450 nm of
16 ± 0.7%, 7 ± 0.3%, 12 ± 0.8% and 16 ± 1.1%, respectively immedi-
ately after their addition; the decreased signals remained almost
constant for 20 min. The data for DOPAC and cortisone are illus-
trated in Fig. 2A and B; findings with the latter agree well with
a report from Pan et al., 2009. In the same year, Tipparaju et al.,Q3
reported cortisone as a poor substrate for Kv2; this was not
Fig. 2. Fluorescence quenching studies of Kv2. Fluorescence spectra of Kv2
before (blue) and 20 min  after mixing (shown in red and green) with 0.5 mM corti-
sone/DOPAC (A and B respectively) showing 16 and 7% reduction in fluorescence at
450 nm.  The change in fluorescence of the Kv2 bound cofactor occurred immedi-
ately after the addition of the inhibitor and remained stable for 20 min. All assays
were carried out as detailed in Section 2. The addition of 10 l DMSO showed no sig-
nificant reduction in the fluorescence spectrum of Kv2 under the conditions used
(data not shown). (For interpretation of the references to color in this figure legend,
the reader is referred to the web version of the article.) Q6
observed in the present study. Indeed, none of the inhibitors tested
identified in this study were Kv2 substrates.
4. Conclusion
Previous studies of modulators of Kv1 channel activity have
focused on cortisone and its analogues (Pan et al., 2008a, 2012).
The present study advances the search for inhibitors of Kv2  by
identifying several new compounds that bind to this subunit that
specifically inhibit substrate turnover and, therefore, are likely to
have a quite different mechanism of action from cortisone which
appears to exert its influence in large part by dissociating Kv from
Kv1.
It is surprising that, given the sequence homology between Kv
proteins and AKR enzymes, there is very little inhibition of this
subunit activity by classical AKR inhibitors; in fact, there are few
compounds that appear to bind tightly to this protein and this
includes substrates (see Pan et al., 2012; Alka et al., 2010).
Interestingly, DOPAC (the acid degradation product of
dopamine) was found to be an effective inhibitor of Kv2.
Dopamine is released by several areas of the brain and these find-
ings make DOPAC a possible in vivo effector of brain Kv2. However,
the concentration at which inhibition was  observed is quite high.
DOPAC is only the second physiological compound shown to inhibit
Kv2 activity. Physiologically, Dopamine undergoes catabolism
by monoamine oxidase to 3,4-dihydroxyphenylacetaldehyde
(DOPAL), which is further oxidised to 3,4-dihydroxyphenylacetic
acid (DOPAC) by aldehyde dehydrogenase. It is unlikely that
DOPAC levels in vivo will approach those used in this study (Jing et
al., 2007) unless in localised microenvironments.
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Scheme 1. Scheme showing partial inhibition of an enzyme catalysed reaction
where E, S and I represent enzyme, substrate and inhibitor, respectively. Terms Kcat
and K′cat represent the catalytic rate constants for the breakdown of the ES and ESI
complexes, respectively (McDonald and Tipton, 2002).
Cortisone was found to influence aldehyde turnover as pre-
dicted, but rutin and resveratrol were at least as effective in this
regard. Resveratrol, a polyphenolic compound found in red wine,
is well known for its cardioprotective (Markus and Morris, 2008;
Nicholson et al., 2008) and anti-cancer effects (Chen et al., 2004;
He et al., 2011). Its observed inhibition of the catalytic activity of
Kv2 may  relate to some of the therapeutic properties exhibited
by resveratrol.
It is acknowledged that the concentrations used to achieve Kv2
inhibition are high and the degree of inhibition does not exceed 40%
in any cases. The lack of inhibition studies in the literature for this
subunit may  be due to difficulties in identifying any molecules that
can bind to Kv2. It is important to note that cortisone does not
greatly inhibit aldehyde turnover by this subunit but it has nonethe-
less been shown to have a significant effect on channel activity (see
Pan et al., 2008a).
It is important to note that while the inhibitors examined here
showed concentration dependence they did not give rise to com-
plete inhibition in any case. This precluded the measurement of IC50
values. Moreover, a plot of enzyme activity versus inhibitor concen-
tration was saturable. Inhibition of this kind is normally regarded
as partial and can be explained by assuming that inhibitor binding
does not fully exclude substrate turnover (Scheme 1).
An alternative explanation, where inhibition is caused by bind-
ing at a site other than the active site in a manner that constrains
substrate binding, is also possible but was discounted on the basis of
the fluorescent quenching studies. Moreover, direct binding of cor-
tisone to the active site was observed previously (Pan et al., 2008a).
Of course, such an explanation might be considered where such
binding gave rise to perturbation of the active site in a way that
caused fluorescence quenching. Further kinetic studies are needed
to distinguish these possibilities.
The compounds described here may  help to provide a start-
ing point to stimulate further exploration of Kv2  inhibitors. In
summary, a number of molecules were identified that bind to and
inhibit Kv2-mediated p-nitrobenzaldehyde reduction, including
the steroid cortisone.
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